Company / R&D Expense
InspireMD, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$13.6M
FY2025
5-year range
$2.2M / $13.6M
FY2021-FY2025
Trend
+70.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has increased for 4 consecutive years, from $2M in FY2021 to $14M in FY2025.
Based on SEC 10-K filings.
$14M in FY2025 with a 5-year CAGR of +35.8%.
Improved from $8M to $14M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +38.3%
- 5-Year CAGR
- +35.8%
- 10-Year CAGR
- -
Key checks
Key Insights
- InspireMD, Inc.'s r&d expense has grown for 4 consecutive years.
- 5-year CAGR of +35.8%, indicating consistent growth.
- In FY2025, r&d expense increased 70.8% year-over-year.
- Lowest r&d expense in the period was in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.42 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $13.6M | +70.8% |
| FY2024 | $8.0M | +2.2% |
| FY2023 | $7.8M | +51.4% |
| FY2022 | $5.2M | +131.0% |
| FY2021 | $2.2M | -24.4% |
| FY2020 | $3.0M | +92.4% |
| FY2019 | $1.5M | +20.3% |
| FY2018 | $1.3M | -1.2% |
| FY2017 | $1.3M | -64.6% |
| FY2016 | $3.6M | -58.3% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026